KEYNOTE 590 PEMBROLIZUMAB - AN OVERVIEW

Clinically important immune-mediated hematologic adverse reactions (together with hemolytic anemia, aplastic anemia, immune thrombocytopenic purpura) transpired at an incidence of fewer than 1% in patients who obtained this drug or have been noted with using other PD-1/PD-L1 blocking antibodies.The rash could be red or purple and then develop into